Retrieve available abstracts of 207 articles: HTML format
Single Articles
June 2025
KAMALLOO H, Fathi M, Bavandi S, Asadi F, et al Recent advances in monoclonal antibody development for treatment of B-cell acute
lymphoblastic leukemia.
Leuk Lymphoma. 2025 Jun 2:1-13. doi: 10.1080/10428194.2025.2507198. PubMedAbstract available
JANY J, Mikesch JH, Wethmar K, Baden D, et al Prognostic impact of WBC kinetics after induction therapy in patients with acute
myeloid leukemia (AML).
Leuk Lymphoma. 2025 Jun 2:1-12. doi: 10.1080/10428194.2025.2512029. PubMedAbstract available
May 2025
LEVY V, Srivastava T, Gautam R, Swami S, et al Toxicity, progression-free survival, and quality of life of patients treated with
zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in
relapsed or refractory chronic lymphocytic leukemia.
Leuk Lymphoma. 2025 May 23:1-9. doi: 10.1080/10428194.2025.2506501. PubMedAbstract available
MEHTA P, Ngo D, Tinajero J, Agrawal V, et al Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia
chromosome negative acute lymphoblastic leukemia in adults >/=40 years old.
Leuk Lymphoma. 2025 May 21:1-5. doi: 10.1080/10428194.2025.2506003. PubMed
SHI C, Li Y, Zou X, Yao D, et al AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor
immune microenvironment in acute myeloid leukemia.
Leuk Lymphoma. 2025 May 19:1-15. doi: 10.1080/10428194.2025.2504161. PubMedAbstract available
HILL JW, Marvin-Peek J, Sasaki K, Bresser S, et al Central nervous system relapse of core-binding factor acute myeloid leukemia.
Leuk Lymphoma. 2025 May 19:1-4. doi: 10.1080/10428194.2025.2506505. PubMed
TADMOR T, Lavie G, Melamed G, Alapi H, et al Intake of benzodiazepines in treatment naive chronic lymphocytic leukemia
patients is associate with a shorter time to first treatment.
Leuk Lymphoma. 2025 May 15:1-6. doi: 10.1080/10428194.2025.2504155. PubMedAbstract available
OTHMAN T, Lo MM, Andreadis CB, Damon LE, et al Single-center experience with nelarabine, etoposide, and cyclophosphamide in
adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma.
Leuk Lymphoma. 2025 May 7:1-4. doi: 10.1080/10428194.2025.2496333. PubMed
GORDON BK, Woyach JA The challenge of targeting key drivers of CLL and sequencing therapy in an era of
experimental therapeutics.
Leuk Lymphoma. 2025;66:838-846. PubMedAbstract available
MCKEAGUE S, Tam C Prognostic factors in chronic lymphocytic leukaemia - the old, the new and the
future.
Leuk Lymphoma. 2025;66:847-857. PubMedAbstract available
RAMACHANDRA N, Vegivinti CTR, Sahu S, Sanawar R, et al Transforming growth factor beta receptor type I (TGF-betaRI) kinase inhibitors
IOA-359 and IOA-360 stimulate erythropoiesis in MDS.
Leuk Lymphoma. 2025;66:920-929. PubMedAbstract available
April 2025
SHALLIS RM, Weiss JJ, Winer ES, Badar T, et al Feasibility and safety of outpatient hypomethylating agent and venetoclax
initiation with and without ramp-up for newly diagnosed acute myeloid leukemia:
results from the Consortium on Myeloid Malignancies and Neoplastic Diseases
(COMMAND).
Leuk Lymphoma. 2025 Apr 28:1-5. doi: 10.1080/10428194.2025.2496339. PubMed
LAGANA A, Kasmi D, Diverio D, Bisegna ML, et al CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications
(FLT3-ITD(mut)-AML): a flow-cytometric marker for an accurate diagnostic workup.
Leuk Lymphoma. 2025 Apr 28:1-6. doi: 10.1080/10428194.2025.2497392. PubMedAbstract available
ELHODAKY M, Duckett D, Santana-Santos L, Oh TS, et al Clinicopathological and global methylation profiling of acute myeloid leukemia
with mutations in NPM1 and clonal hematopoiesis-related genes.
Leuk Lymphoma. 2025 Apr 25:1-8. doi: 10.1080/10428194.2025.2495105. PubMedAbstract available
BEHMAN J, Longobardi S, Kang G, Lingamurthy M, et al CD5- B-cell lymphocytic leukemia -a diagnostic exclusion of splenic B-cell
leukemia with prominent nuclei challenging current international consensus.
Leuk Lymphoma. 2025 Apr 22:1-4. doi: 10.1080/10428194.2025.2492608. PubMed
LEVANON E, Peles I, Meyer E, Tarab E, et al Prognostic impact of fever at presentation in acute myeloid leukemia: a
retrospective cohort study.
Leuk Lymphoma. 2025 Apr 17:1-11. doi: 10.1080/10428194.2025.2493342. PubMedAbstract available
PATEL M, Zabor EC, Mohamed A, Zureigat H, et al Impact of TP53 mutation on survival outcomes in acute lymphoblastic leukemia at a
tertiary center.
Leuk Lymphoma. 2025 Apr 9:1-6. doi: 10.1080/10428194.2025.2482131. PubMedAbstract available
DHAKAL P, Armitage JO, Bhatt VR Academic and community cancer center collaboration in acute myeloid leukemia: a
road map to optimize care delivery.
Leuk Lymphoma. 2025 Apr 1:1-11. doi: 10.1080/10428194.2025.2484640. PubMedAbstract available
March 2025
KUGLER E, Dasdemir E, Bataller A, Wang B, et al Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with
chromosomal 7 deletions.
Leuk Lymphoma. 2025 Mar 31:1-13. doi: 10.1080/10428194.2025.2477723. PubMedAbstract available
JOHANSSON ALM S, Orrsjo G, Shah Barkhordar G, Rehammar A, et al Prognostic significance of deep sequencing for analysis of measurable residual
disease in acute myeloid leukemia with NPM1 mutation.
Leuk Lymphoma. 2025 Mar 31:1-11. doi: 10.1080/10428194.2025.2482130. PubMedAbstract available
FERREIRA JE, Wang CP, Aguayo-Hiraldo P, Raca G, et al Achievement of durable remission of relapsed/refractory acute myeloid leukemia in
a child using venetoclax monotherapy.
Leuk Lymphoma. 2025 Mar 25:1-5. doi: 10.1080/10428194.2025.2482135. PubMed
ROBAK T, Pluta A, Robak P, Janus A, et al Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent
B-cell lymphoid malignancies.
Leuk Lymphoma. 2025 Mar 25:1-13. doi: 10.1080/10428194.2025.2475337. PubMedAbstract available
JAIN N, Eyre TA, Winfree KB, Bhandari NR, et al Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy
in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leuk Lymphoma. 2025 Mar 23:1-13. doi: 10.1080/10428194.2025.2482132. PubMedAbstract available
MONSEES EL, Hauch RT, Wrzeszcz A, Spohn M, et al A case report of a pediatric T-cell acute lymphoblastic leukemia with a subclonal
GCC2::PDGFRB t(2;5) translocation - implementation for the selection of
MRD-targets.
Leuk Lymphoma. 2025 Mar 19:1-5. doi: 10.1080/10428194.2025.2480395. PubMed
AMREIN PC, Preffer FI, Fell G, Attar EC, et al Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia
in older adults.
Leuk Lymphoma. 2025 Mar 12:1-11. doi: 10.1080/10428194.2025.2476655. PubMedAbstract available
HOECHSTETTER MA, Wendtner CM Clinical trials in early-stage CLL: what has been learned and what's next?
Leuk Lymphoma. 2025;66:378-388. PubMedAbstract available
ALHAJAHJEH A, Patel KK, Shallis RM, Podoltsev NA, et al Cost-effectiveness of Enasidenib versus conventional care for older patients with
IDH2-mutant refractory/relapsed AML.
Leuk Lymphoma. 2025;66:488-496. PubMedAbstract available
LI Q, Xing S, Zhang H, Mao X, et al FISH combined with RT-PCR facilitates classification of Chinese adult patients
with B-other ALL through improved identification of ZNF384 rearrangement.
Leuk Lymphoma. 2025;66:507-515. PubMedAbstract available
February 2025
TAN M, Lasica M, Donati V, Rady K, et al Avascular necrosis in older adolescents and adults with acute lymphoblastic
leukemia treated with FRALLE protocols: a multicenter analysis of incidence, risk
factors and morbidity.
Leuk Lymphoma. 2025 Feb 27:1-7. doi: 10.1080/10428194.2025.2470784. PubMedAbstract available
GRUESSNER C, Wiestner A, Sun C Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK
inhibitor therapy.
Leuk Lymphoma. 2025 Feb 19:1-13. doi: 10.1080/10428194.2025.2466101. PubMedAbstract available
SHESTAKOVA A, Haghighi N, Zhang Y, Tarabay J, et al Mutational landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) involving the central nervous system.
Leuk Lymphoma. 2025 Feb 18:1-6. doi: 10.1080/10428194.2025.2452341. PubMed
SUN Y, Liu N, Liu Y, Deng J, et al Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic
hematopoietic stem cell transplantation in adult acute myeloid leukemia with
KMT2A::MLLT1 rearrangement.
Leuk Lymphoma. 2025 Feb 10:1-4. doi: 10.1080/10428194.2025.2460046. PubMed
THOMAS CJ, Porter D, Van Deerlin VM, Bhattacharyya S, et al Aleukemic soft-tissue relapse post allogeneic hematopoietic cell transplantation
in T-prolymphocytic leukemia.
Leuk Lymphoma. 2025 Feb 8:1-4. doi: 10.1080/10428194.2025.2462950. PubMed
LANG F, Voss A, Kobbe G, Junghanss C, et al Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy
in combination with dasatinib in first line treatment of Philadelphia chromosome
positive acute lymphoblastic leukemia.
Leuk Lymphoma. 2025 Feb 8:1-9. doi: 10.1080/10428194.2025.2460737. PubMedAbstract available
CHIN KK, Derkach A, Famulare C, Gupta GK, et al HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.
Leuk Lymphoma. 2025;66:270-278. PubMedAbstract available
January 2025
KRSTEVSKA BOZHINOVIKJ E, Matevska-Geshkovska N, Staninova Stojovska M, Gjorgievska E, et al Presence of minimal residual disease determined by next-generation sequencing is
not a reliable prognostic biomarker in children with acute lymphoblastic
leukemia.
Leuk Lymphoma. 2025 Jan 22:1-8. doi: 10.1080/10428194.2025.2456100. PubMedAbstract available
JEONG Y Comprehensive analysis of clinical, pathological, and molecular features in
chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutations and higher
mutation burden in myeloproliferative CMML compared to myelodysplastic CMML.
Leuk Lymphoma. 2025 Jan 17:1-10. doi: 10.1080/10428194.2025.2453093. PubMedAbstract available
TESSIER S, McCullough KB, Gangat N, Begna KH, et al Venetoclax in combination with fludarabine, cytarabine, granulocyte colony
stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of
ambiguous lineage and acute lymphoblastic leukemia.
Leuk Lymphoma. 2025 Jan 16:1-5. doi: 10.1080/10428194.2024.2443017. PubMed
HEILBRONNER AK, Blumberg O, Krez A, McMahon DJ, et al High incidence of multi-joint osteonecrosis in first year following treatment for
acute lymphoblastic leukemia.
Leuk Lymphoma. 2025 Jan 15:1-4. doi: 10.1080/10428194.2025.2452340. PubMed
ZHU H, Zhang C, Huang L, Zhang B, et al Identification of possible drug treatment targets and related immune cell
infiltration properties in acute myeloid leukemia utilizing robust rank
aggregation algorithm.
Leuk Lymphoma. 2025 Jan 15:1-12. doi: 10.1080/10428194.2025.2451064. PubMedAbstract available
LI M, Zhao DQ, Kong XY, Wang SM, et al Effects of SCT genetic polymorphisms on methotrexate concentrations and
toxicities in Chinese children with acute lymphoblastic leukemia.
Leuk Lymphoma. 2025 Jan 11:1-11. doi: 10.1080/10428194.2025.2451059. PubMedAbstract available
SENAPATI J, Kantarjian H, Habib D, Haddad FG, et al Frontline immunotherapeutic combination strategies in adult B-cell acute
lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and
harnessing efficacy.
Leuk Lymphoma. 2025 Jan 10:1-12. doi: 10.1080/10428194.2025.2449582. PubMedAbstract available
ZHANG F, Liu Y, Zhu Y, Wang Q, et al Molecular, clinical, and prognostic implications of RAS pathway alterations in
adult acute myeloid leukemia.
Leuk Lymphoma. 2025 Jan 2:1-11. doi: 10.1080/10428194.2024.2441855. PubMedAbstract available
YSEBAERT L, Mouchel PL, Laurent C, Quillet-Mary A, et al The multi-faceted roles of MYC in the prognosis of chronic lymphocytic leukemia.
Leuk Lymphoma. 2025 Jan 2:1-13. doi: 10.1080/10428194.2024.2447362. PubMedAbstract available
December 2024
AVGERINOU G, Solomou EE, Filippidou M, Perganti F, et al Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in
children with acute promyelocytic leukemia.
Leuk Lymphoma. 2024 Dec 28:1-4. doi: 10.1080/10428194.2024.2445701. PubMed
GUGLIELMANA V, Rossi D Prognostic and predictive impact of NOTCH1 mutation in chronic lymphocytic
leukemia: a systematic review.
Leuk Lymphoma. 2024 Dec 27:1-10. doi: 10.1080/10428194.2024.2441858. PubMedAbstract available
NILSSON MS, Martner A, Wennstrom L, Hansson M, et al Consistency of the efficacy of immunotherapy with histamine dihydrochloride and
low-dose interleukin-2 for relapse prevention in acute myeloid leukemia.
Leuk Lymphoma. 2024 Dec 24:1-3. doi: 10.1080/10428194.2024.2444466. PubMed
DAMPMANN M, Kibler A, von Tresckow J, Reinhardt HC, et al Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two
clones with distinct gene expression pattern.
Leuk Lymphoma. 2024 Dec 17:1-9. doi: 10.1080/10428194.2024.2438804. PubMedAbstract available
OLIAI C, Park S, Damon LE, Jonas BA, et al CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous
leukemia: a University of California Hematologic Malignancies Consortium trial.
Leuk Lymphoma. 2024 Dec 17:1-7. doi: 10.1080/10428194.2024.2438809. PubMedAbstract available
SHELLEY CS, Galiegue-Zouitina S, Andritsos LA, Epperla N, et al The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its
ability to identify existing therapeutics that could be repurposed to treat
relapsed or refractory disease.
Leuk Lymphoma. 2024 Dec 17:1-19. doi: 10.1080/10428194.2024.2438800. PubMedAbstract available
ISHIKAWA C, Mori N ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of
adult T-cell leukemia.
Leuk Lymphoma. 2024 Dec 17:1-12. doi: 10.1080/10428194.2024.2441875. PubMedAbstract available
KOVACH AE, Komova D, Itov A, Gaskova M, et al Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A
rearrangement and lymphoblastic phenotype.
Leuk Lymphoma. 2024;65:1840-1852. PubMedAbstract available
MINA A Targeted therapy in acute T-cell leukemia/lymphoma: are we close?
Leuk Lymphoma. 2024 Dec 1:1-3. doi: 10.1080/10428194.2024.2432575. PubMed
PAISIOU A, OIkonomopoulou C, Pavlidis D, Ampatzidou M, et al CDKN2A/B deletion as an independent negative prognostic factor for allogeneic
hematopoietic stem cell transplantation in childhood B cell precursor acute
lymphoblastic leukemia.
Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2434177. PubMed
RIOS-OLAIS FA, Rodriguez-Rodriguez S, Mora-Canas A, Ramos-Penafiel CO, et al Impact of the addition of rituximab in adults with newly diagnosed Philadelphia
chromosome-positive acute lymphoblastic leukemia.
Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2432582. PubMed
EHRMANN AS, Zadro A, Tausch E, Schneider C, et al The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL.
Leuk Lymphoma. 2024;65:1941-1953. PubMedAbstract available
ARAD-COHEN N, Messinger Y, Barzilai-Birenboim S, Ben-Harosh M, et al National study reveals gram negative bacteremia on contemporary pediatric AML
protocol.
Leuk Lymphoma. 2024;65:1991-1999. PubMedAbstract available
TASHAKORI M, Yohe S, Linden MA, McKenna RW, et al The prognostic effect of blast count in TP53 mutant myeloid neoplasms -the
Minnesota experience.
Leuk Lymphoma. 2024;65:2151-2162. PubMedAbstract available
BOHN JP, Stolzlechner V, Gobel G, Pirklbauer M, et al Reduced prognostic value of beta-2-microglobulin for time to first treatment in
CLL patients with compromised kidney function.
Leuk Lymphoma. 2024;65:2108-2115. PubMedAbstract available
November 2024
PAUL S, Jabbour E, Nichols ED, Short NJ, et al Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world
setting: clinical vignettes.
Leuk Lymphoma. 2024 Nov 29:1-11. doi: 10.1080/10428194.2024.2426052. PubMedAbstract available
SHORT NJ, Wierzbowska A, Cluzeau T, Laribi K, et al Azacitidine and venetoclax with or without pevonedistat in patients with newly
diagnosed acute myeloid leukemia.
Leuk Lymphoma. 2024 Nov 28:1-11. doi: 10.1080/10428194.2024.2431878. PubMedAbstract available
MIMS A, Xie Z, Potluri R, Rotter D, et al Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and
azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia.
Leuk Lymphoma. 2024 Nov 28:1-9. doi: 10.1080/10428194.2024.2425792. PubMedAbstract available
COSTA A, Scalzulli E, Carmosino I, Ielo C, et al Clinical and biological advances of critical complications in acute myeloid
leukemia.
Leuk Lymphoma. 2024 Nov 24:1-20. doi: 10.1080/10428194.2024.2425051. PubMedAbstract available
ARRIGO G, Scaldaferri M, Audisio E, Boscaro E, et al Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single
center experience.
Leuk Lymphoma. 2024 Nov 8:1-2. doi: 10.1080/10428194.2024.2427266. PubMed
KORSHOLM C, Bulow C, Christensen M, Dalhoff K, et al Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a
systematic review.
Leuk Lymphoma. 2024 Nov 7:1-11. doi: 10.1080/10428194.2024.2412289. PubMedAbstract available
LECORNEC N, Duchmann M, Itzykson R Single-cell sequencing applications in acute myeloid leukemia.
Leuk Lymphoma. 2024 Nov 4:1-15. doi: 10.1080/10428194.2024.2422833. PubMedAbstract available
TAM C, Zhao FL, Azam S, Li SC, et al Real-world treatment patterns and outcomes for patients with CLL using the
Australian pharmaceutical benefits scheme (PBS) dataset.
Leuk Lymphoma. 2024;65:1576-1585. PubMedAbstract available
October 2024
THARAKAN S, Tremblay D, Azzi J Adoptive cell therapy in acute myeloid leukemia: the current landscape and
emerging strategies.
Leuk Lymphoma. 2024 Oct 25:1-14. doi: 10.1080/10428194.2024.2414112. PubMedAbstract available
ROTTER LK, Alhajahjeh A, Stempel JM, Grimshaw AA, et al Analyzing determinants of premature trial discontinuation in leukemia clinical
trials.
Leuk Lymphoma. 2024 Oct 23:1-9. doi: 10.1080/10428194.2024.2416565. PubMedAbstract available
KIM SA, Jung M, Kim H, Byun JM, et al MG4101, an allogeneic natural killer cell, in patients with relapsed or
refractory acute myeloid leukemia: a pilot study.
Leuk Lymphoma. 2024 Oct 22:1-8. doi: 10.1080/10428194.2024.2414903. PubMedAbstract available
DEHGHANI SS, Wang Y, Ramesh KH, Cooper D, et al Atypical chronic myeloid leukemia (CML) with ETV6-ABL1 mutation managed
successfully with a third-generation TKI and hematopoietic stem cell transplant.
Leuk Lymphoma. 2024 Oct 18:1-3. doi: 10.1080/10428194.2024.2403666. PubMed
RIBERA JM, Torrent A Novel prognostic factors and therapeutic advances in adult acute lymphoblastic
leukemia.
Leuk Lymphoma. 2024 Oct 18:1-11. doi: 10.1080/10428194.2024.2416569. PubMedAbstract available
KANKARIA RA, Jones JB, Zargari M, Alexander DW, et al Complete remission in a case of acute undifferentiated leukemia with novel
combination therapy of FLAG-IDA and venetoclax.
Leuk Lymphoma. 2024 Oct 16:1-4. doi: 10.1080/10428194.2024.2416573. PubMed
MOHAMMAD EM, El-Ayadi M, Kamel A, Ebeid E, et al Early impact of treatment modifications adopted for acute lymphoblastic leukemia
during SARS-CoV-2 pandemic; a single center experience and lessons for LMICs.
Leuk Lymphoma. 2024 Oct 9:1-7. doi: 10.1080/10428194.2024.2411432. PubMedAbstract available
SHANG Q, Wang Y, Lu A, Jia Y, et al Impact of pre-infusion disease burden on outcomes in pediatric
relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell
therapy.
Leuk Lymphoma. 2024 Oct 8:1-10. doi: 10.1080/10428194.2024.2406958. PubMedAbstract available
BRUNER SA, DiPippo AJ, Rausch CR Dose-adjusted direct oral anticoagulants (DOACs) in patients with acute leukemia:
experience of a tertiary cancer care center.
Leuk Lymphoma. 2024 Oct 7:1-3. doi: 10.1080/10428194.2024.2411626. PubMed
SHADMAN M, Salkar M, Srivastava B, Karve S, et al Real-world outcomes following ibrutinib dose reduction in patients with chronic
lymphocytic leukemia/small lymphocytic lymphoma.
Leuk Lymphoma. 2024 Oct 1:1-10. doi: 10.1080/10428194.2024.2402814. PubMedAbstract available
September 2024
ZABLONSKI KG, Skupa SA, Eiken AP, Sundaram S, et al Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic
lymphocytic leukemia.
Leuk Lymphoma. 2024 Sep 27:1-9. doi: 10.1080/10428194.2024.2398663. PubMedAbstract available
SHANGGUAN X, Huang Y, Chen C, Wu W, et al Prognostic assessment value of immune escape-related genes in patients with acute
myeloid leukemia.
Leuk Lymphoma. 2024 Sep 23:1-12. doi: 10.1080/10428194.2024.2404957. PubMedAbstract available
KOPMAR NE, Qu X, Liu Y, Gooley TA, et al Prognostic significance of chromosomal genomic array testing in adults with
newly-diagnosed acute lymphoblastic leukemia.
Leuk Lymphoma. 2024 Sep 19:1-4. doi: 10.1080/10428194.2024.2404959. PubMed
DE SA H, Deloughery T, Kaempf A, Lachowiez C, et al Thromboprophylaxis with intermediate dose enoxaparin during asparaginase
containing induction for young adults with acute lymphoblastic leukemia.
Leuk Lymphoma. 2024 Sep 18:1-10. doi: 10.1080/10428194.2024.2405874. PubMedAbstract available
OMRAN MM, Ibrahim AB, Abdelfattah R, Moussa HS, et al The interplay of knowledge, motivation, and treatment response in medication
adherence among patients with chronic myeloid leukemia treated with Imatinib.
Leuk Lymphoma. 2024 Sep 18:1-8. doi: 10.1080/10428194.2024.2403671. PubMedAbstract available
CHEN EC, Flamand Y, Tiao E, DeAngelo DJ, et al Incidence, duration, and severity of neutropenia in adults with B-cell acute
lymphoblastic leukemia receiving blinatumomab consolidation.
Leuk Lymphoma. 2024 Sep 16:1-8. doi: 10.1080/10428194.2024.2402808. PubMedAbstract available
YIN Z, Gao Y, Bu X, Wang J, et al Homoharringtonine sensitized resistant acute myeloid leukemia cells to
venetoclax-induced apoptosis.
Leuk Lymphoma. 2024 Sep 5:1-13. doi: 10.1080/10428194.2024.2400228. PubMedAbstract available
HUNTER S, Ryland G, Pang JM, Ninkovic S, et al Chronic lymphocytic leukemia with MDM2 amplification as an alternative pathway to
TP53 dysfunction.
Leuk Lymphoma. 2024 Sep 4:1-4. doi: 10.1080/10428194.2024.2398659. PubMed
GIL KB, Abbott D, Amaya ML, Schwartz M, et al Response to intensive induction chemotherapy after failure of frontline
azacitidine and venetoclax in acute myeloid leukemia.
Leuk Lymphoma. 2024 Sep 4:1-3. doi: 10.1080/10428194.2024.2397570. PubMed
DEODATO M, Frustaci AM, Zappaterra A, Rapella A, et al Advances in the understanding of molecular genetics and therapy of Richter
transformation in chronic lymphocytic leukemia.
Leuk Lymphoma. 2024 Sep 2:1-12. doi: 10.1080/10428194.2024.2398660. PubMedAbstract available
HAYASHI H, Morikawa Y, Akahoshi S, Ikegawa K, et al Octreotide as prophylaxis against asparaginase-associated pancreatitis: a case
series study.
Leuk Lymphoma. 2024;65:1366-1369. PubMed
RAVANDI F, Subklewe M, Walter RB, Vachhani P, et al Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a
phase 1a dose-escalation study.
Leuk Lymphoma. 2024;65:1281-1291. PubMedAbstract available
ABUASAB T, Mohamed S, Pemmaraju N, Kadia TM, et al BRAF mutation in myeloid neoplasm: incidences and clinical outcomes.
Leuk Lymphoma. 2024;65:1344-1349. PubMedAbstract available
SABILE JMG, Swords R, Tyner JW Evaluating targeted therapies in older patients with TP53-mutated AML.
Leuk Lymphoma. 2024;65:1201-1218. PubMedAbstract available
KOBAYASHI Y, Ando K, Imaizumi Y, Sakamoto H, et al RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in
adult T-cell leukemia/lymphoma.
Leuk Lymphoma. 2024 Sep 1:1-13. doi: 10.1080/10428194.2024.2393258. PubMedAbstract available
August 2024
SCHWARTZ MS, Muffly LS Predicting relapse in acute lymphoblastic leukemia.
Leuk Lymphoma. 2024 Aug 31:1-7. doi: 10.1080/10428194.2024.2387728. PubMedAbstract available
OSTERGAARD A, Boer JM, van Leeuwen FN, Pieters R, et al IKZF1 in acute lymphoblastic leukemia: the rise before the fall?
Leuk Lymphoma. 2024 Aug 29:1-11. doi: 10.1080/10428194.2024.2396046. PubMedAbstract available
NGO D, Tinajero J, Song JY, Ma H, et al The characterization and the impact of CSF pleocytosis during blinatumomab
therapy for adult acute lymphoblastic leukemia.
Leuk Lymphoma. 2024 Aug 18:1-9. doi: 10.1080/10428194.2024.2392823. PubMedAbstract available
PRASERTSAN P, McNeil EB, Songthawee N, Chavananon S, et al Risk factors and development of a predictive score model for tumor lysis syndrome
in childhood leukemia: a 10-year experience from a single tertiary hospital in
Thailand.
Leuk Lymphoma. 2024 Aug 18:1-7. doi: 10.1080/10428194.2024.2390582. PubMedAbstract available
JEANSELME P, Tavitian S, Lapierre L, Vergez F, et al Long-term exposure and response to azacitidine for post-hematopoietic stem cell
transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a
case report and review of the literature.
Leuk Lymphoma. 2024 Aug 14:1-6. doi: 10.1080/10428194.2024.2390572. PubMedAbstract available
CELLINI A, Salvalaggio A, Velasco R, Arnan M, et al Arsenic trioxide-induced peripheral neuropathy: prospective clinical and
neurophysiological evaluation in a cohort of patients with acute promyelocytic
leukemia.
Leuk Lymphoma. 2024 Aug 13:1-4. doi: 10.1080/10428194.2024.2391899. PubMed
PELLAND AA, Deschenes-Simard X, Savard X, Giguere P, et al Outcomes of adults with refractory or relapsed acute myeloid leukemia treated
with azacitidine and venetoclax compared to other therapies: a multicenter
retrospective study.
Leuk Lymphoma. 2024 Aug 11:1-9. doi: 10.1080/10428194.2024.2390574. PubMedAbstract available
HU D, Shen K, Guo Y, Bao XB, et al The clinical implications of BCOR mutations in a large cohort of acute myeloid
leukemia patients: a 5-year single-center retrospective study.
Leuk Lymphoma. 2024 Aug 10:1-10. doi: 10.1080/10428194.2024.2387730. PubMedAbstract available
LIN L, Xue S, Chen J, Gu C, et al Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive
acute myeloid leukemia in elderly patient.
Leuk Lymphoma. 2024;65:1181-1185. PubMed
VERVOORDELDONK MYL, Hengeveld PJ, Levin MD, Langerak AW, et al B cell receptor signaling proteins as biomarkers for progression of CLL requiring
first-line therapy.
Leuk Lymphoma. 2024;65:1031-1043. PubMedAbstract available
MAEKAWA F, Hayashida M, Takeoka K, Fukutsuka K, et al Two recurrent types of IGH::5' BCL2 breakpoints representing cytogenetic
ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class
switch recombination processes, respectively.
Leuk Lymphoma. 2024;65:1100-1109. PubMedAbstract available
CHARALAMPOUS C, Doucette K, Chappell A, Vesole DH, et al Venetoclax-based induction therapy for primary plasma cell leukemia with high
BCL-2 expression.
Leuk Lymphoma. 2024 Aug 1:1-4. doi: 10.1080/10428194.2024.2381647. PubMed
July 2024
DALAL P, Dalal J PTCy-ATG mutually exclusive or additive? Anti-thymocyte globulin combined with
post-transplantation cyclophosphamide reduce graft-versus-host disease in
hematopoietic stem cell transplantation for pediatric leukemia.
Leuk Lymphoma. 2024 Jul 31:1-2. doi: 10.1080/10428194.2024.2379976. PubMed
CHOI YJ, Kook HW, Lee ST, Song J, et al The utility of next generation sequencing-based minimal residual disease
monitoring in a post-myeloproliferative neoplasm acute myeloid leukemia patient:
a case report.
Leuk Lymphoma. 2024 Jul 29:1-4. doi: 10.1080/10428194.2024.2385498. PubMed
JAIN U, Rahim F, Jain B, Tresa Mathew A, et al Trends in location of death for individuals with acute myeloid leukemia in the
United States.
Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2382330. PubMed
ZHANG B, Mahsoub S, Weinberg O, Germans SK, et al Clinicopathologic characteristics of de novo NF1-mutated acute myeloid leukemia.
Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2382329. PubMed
SRIPORNSAWAN P, Chavananon S, Kittivisuit S, Songthawee N, et al Long-term survival outcome of childhood acute myeloid leukemia: a 43-year
experience in Thailand, a resource-limited country.
Leuk Lymphoma. 2024 Jul 26:1-10. doi: 10.1080/10428194.2024.2382916. PubMedAbstract available
TOHO M, Yasunaga M, Masuda Y, Shimura A, et al Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by
valemetostat: a case report and review of literature.
Leuk Lymphoma. 2024 Jul 25:1-5. doi: 10.1080/10428194.2024.2381646. PubMed
FANG J, Shankar N, Bao L, Haag M, et al Near-tetraploidy/tetraploidy acute myeloid leukemia with clinical, pathologic and
molecular characteristics.
Leuk Lymphoma. 2024 Jul 25:1-10. doi: 10.1080/10428194.2024.2382923. PubMedAbstract available
TARANTINI F, Cumbo C, Anelli L, Zagaria A, et al Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the
path to allogeneic hematopoietic stem cell transplant?
Leuk Lymphoma. 2024 Jul 23:1-12. doi: 10.1080/10428194.2024.2381649. PubMedAbstract available
MORENO-LORENZANA D, Juarez-Velazquez R, Reyes-Leon A, Martinez-Anaya D, et al CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than
B-cell Acute Lymphoblastic Leukemia.
Leuk Lymphoma. 2024 Jul 21:1-11. doi: 10.1080/10428194.2024.2378817. PubMedAbstract available
TRAN QUANG V, Wagner-Ballon O, Sloma I Predicting which subsets of patients with myelodysplastic neoplasms are more
likely to progress to overt chronic myelomonocytic leukemia.
Leuk Lymphoma. 2024 Jul 14:1-11. doi: 10.1080/10428194.2024.2378816. PubMedAbstract available
BORSOI L, Costa F, Milano C, Segantin G, et al Elicitation of societal preferences for chronic lymphocytic leukemia's
treatments: a discrete choice experiment.
Leuk Lymphoma. 2024 Jul 9:1-11. doi: 10.1080/10428194.2024.2374041. PubMedAbstract available
HU M, Li J, Hu T, Zhang Z, et al Anti-thymocyte globulin combined with post-transplantation cyclophosphamide
reduce graft-versus-host disease in hematopoietic stem cell transplantation for
pediatric leukemia.
Leuk Lymphoma. 2024 Jul 7:1-10. doi: 10.1080/10428194.2024.2376179. PubMedAbstract available
DIEBOLD K, Bourne G, Espinoza-Gutarra M, Al-Kadhimi Z, et al Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute
myeloid leukemia.
Leuk Lymphoma. 2024 Jul 7:1-3. doi: 10.1080/10428194.2024.2373324. PubMed
TORELI ACM, Miranda-Galvis M, Sharara M, Addas-Carvalho M, et al Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid
leukemia patients: insights from real-world data in Brazil and the United States.
Leuk Lymphoma. 2024 Jul 5:1-10. doi: 10.1080/10428194.2024.2367057. PubMedAbstract available
LAVIE G, Tadmor T It's time to change the standard of care for hairy cell leukemia?!
Leuk Lymphoma. 2024 Jul 5:1-3. doi: 10.1080/10428194.2024.2371497. PubMed
ALHAJAHJEH A, Bewersdorf JP, Bystrom RP, Zeidan AM, et al Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management,
and clinical outcome.
Leuk Lymphoma. 2024 Jul 4:1-11. doi: 10.1080/10428194.2024.2367040. PubMedAbstract available
TAKIZAWA J, Teshima T, Ennishi D, Ichikawa S, et al Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic
lymphocytic leukemia: a Japanese phase 1 study.
Leuk Lymphoma. 2024 Jul 1:1-9. doi: 10.1080/10428194.2024.2370436. PubMedAbstract available
SURESH D, Rastogi P, Bal A, Lad D, et al Bridging the gap: understanding contemporary autopsies in acute leukemia by
comparing ante-mortem and post-mortem profiles.
Leuk Lymphoma. 2024 Jul 1:1-16. doi: 10.1080/10428194.2024.2372408. PubMedAbstract available
GOERGEN E, Al-Sawaf O The prognostic significance of genomic complexity in patients with CLL.
Leuk Lymphoma. 2024;65:873-881. PubMedAbstract available
June 2024
ANDERSON LJ, Girguis M, Kim E, Shewale J, et al A temporal and multinational assessment of acute myeloid leukemia (AML) cancer
incidence, survival, and disease burden.
Leuk Lymphoma. 2024 Jun 27:1-10. doi: 10.1080/10428194.2024.2360536. PubMedAbstract available
YU G, Zhang W, Basyal M, Nishida Y, et al The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute
myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.
Leuk Lymphoma. 2024 Jun 13:1-16. doi: 10.1080/10428194.2024.2364839. PubMedAbstract available
ABE C, Keto J, Lilja M, Konradsen M, et al Cytarabine dose intensification improves survival in older patients with
secondary/high-risk acute myeloid leukemia in matched real-world versus clinical
trial data.
Leuk Lymphoma. 2024 Jun 11:1-9. doi: 10.1080/10428194.2024.2363430. PubMedAbstract available
BHATLA T, Cooper S, Hogan LE Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what
have we learnt and what's next?
Leuk Lymphoma. 2024 Jun 11:1-7. doi: 10.1080/10428194.2024.2362408. PubMedAbstract available
CHANG JE, Wang T, Kim K, Folstad M, et al Maintenance low-dose fixed duration lenalidomide and rituximab following
bendamustine and rituximab induction in previously untreated chronic lymphocytic
leukemia and small lymphocytic lymphoma.
Leuk Lymphoma. 2024 Jun 10:1-9. doi: 10.1080/10428194.2024.2360535. PubMedAbstract available
SHORT NJ, Kantarjian H, Jabbour E Advances in the treatment of adults with newly diagnosed B-cell acute
lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
Leuk Lymphoma. 2024 Jun 8:1-13. doi: 10.1080/10428194.2024.2364043. PubMedAbstract available
GERA K, Cline C, Al-Mansour Z, Medvec A, et al A phase ib clinical trial of oral ciprofloxacin and etoposide in subjects with
resistant acute myeloid leukemia.
Leuk Lymphoma. 2024 Jun 6:1-9. doi: 10.1080/10428194.2024.2361111. PubMedAbstract available
SHOUSE G, Chen L, Siddiqi T, Muir A, et al A phase II study of induction followed by intermittent duvelisib dosing in
patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Leuk Lymphoma. 2024 Jun 5:1-4. doi: 10.1080/10428194.2024.2361841. PubMed
FREI CR, Ryan K, Obodozie-Ofoegbu GO, Moore AM, et al Shift in first-line therapies for United States Veterans Affairs (VA) patients
with chronic lymphocytic leukemia (CLL).
Leuk Lymphoma. 2024 Jun 4:1-4. doi: 10.1080/10428194.2024.2360526. PubMed
FANG J, Bosma G, Aisner D, McMahon C, et al White blood cell count nadir to zero following intensive chemotherapy as a
predictive factor for patients with acute myeloid leukemia.
Leuk Lymphoma. 2024;65:800-807. PubMedAbstract available
May 2024
MINNEMA MC, Yin X, Davi R, Keeping S, et al Outcomes of patients aged >/=26 years with relapsed or refractory B-cell acute
lymphoblastic leukemia in ZUMA-3 and historical trials.
Leuk Lymphoma. 2024 May 24:1-10. doi: 10.1080/10428194.2024.2353877. PubMedAbstract available
BELDZINSKA-GADEK K, Zarzycka E, Pastuszak K, Borman K, et al Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to
acute myeloid leukemia.
Leuk Lymphoma. 2024 May 22:1-11. doi: 10.1080/10428194.2024.2351194. PubMedAbstract available
ZHENG Y, Li J, Wen H, Weng K, et al Experience in improving treatment outcomes for childhood acute lymphoblastic
leukemia: real-world results for a province in China, 2011-2020.
Leuk Lymphoma. 2024 May 20:1-11. doi: 10.1080/10428194.2024.2350665. PubMedAbstract available
MARVIN-PEEK J, Jen WY, Kantarjian HM, McCue D, et al Long-term results of the sequential combination of cladribine and rituximab in
Hairy cell leukemia.
Leuk Lymphoma. 2024 May 15:1-10. doi: 10.1080/10428194.2024.2349700. PubMedAbstract available
DESPAS F, Chaouki M, de Barros S, Bonneau B, et al Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular
lymphoma disclose better outcomes for patients with lower exposure.
Leuk Lymphoma. 2024 May 15:1-3. doi: 10.1080/10428194.2024.2353330. PubMed
WANG CP, Ferreira JE, Placek A, Aguayo-Hiraldo P, et al A de novo germline RUNX1 variant preceding development of concurrent
T-lymphoblastic leukemia and myelodysplastic syndrome.
Leuk Lymphoma. 2024 May 11:1-5. doi: 10.1080/10428194.2024.2347577. PubMedAbstract available
HUNTINGTON SF, Cheng WY, Sarpong EM, Leng S, et al Real-world patterns and sequences of targeted therapy use in chronic lymphocytic
leukemia and small lymphocytic lymphoma in the United States: a longitudinal
study.
Leuk Lymphoma. 2024 May 2:1-11. doi: 10.1080/10428194.2024.2331631. PubMedAbstract available
ROGERS KA, Thompson PA Pairing obinutuzumab with venetoclax in relapsed CLL.
Leuk Lymphoma. 2024;65:543-545. PubMed
GARCIAZ S, Berton G, Hospital MA, Guille A, et al Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive
molecular data available.
Leuk Lymphoma. 2024;65:700-703. PubMed
OKABE S, Moriyama M, Gotoh A Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive
cells.
Leuk Lymphoma. 2024;65:696-699. PubMed
FATIMA N, Shen Y, Crassini K, Burling O, et al The CIpP activator, TR-57, is highly effective as a single agent and in
combination with venetoclax against CLL cells in vitro.
Leuk Lymphoma. 2024;65:585-597. PubMedAbstract available
April 2024
NESR G, Claudiani S, Milojkovic D, Innes A, et al Effect of tyrosine kinase inhibitors on male fertility in patients with chronic
phase chronic myeloid leukemia.
Leuk Lymphoma. 2024 Apr 23:1-6. doi: 10.1080/10428194.2024.2343758. PubMedAbstract available
STEMPEL JM, Shallis RM, Wong R, Podoltsev NA, et al Challenges in management of older patients with chronic myeloid leukemia.
Leuk Lymphoma. 2024 Apr 23:1-14. doi: 10.1080/10428194.2024.2342559. PubMedAbstract available
BEWERSDORF JP, Patel KK, Shallis RM, Podoltsev NA, et al Cost-effectiveness of adding quizartinib to induction chemotherapy for patients
with FLT3-mutant acute myeloid leukemia.
Leuk Lymphoma. 2024 Apr 22:1-9. doi: 10.1080/10428194.2024.2344052. PubMedAbstract available
FLECK C, Karabinos A, Cook A, Moore DC, et al Evaluation of safety outcomes with transitioning obinutuzumab from standard rate
to short duration infusion in patients with chronic lymphocytic leukemia.
Leuk Lymphoma. 2024 Apr 22:1-2. doi: 10.1080/10428194.2024.2341999. PubMed
TINAJERO J, Ngo D, Zhang J, Tsai NC, et al High remission rates and transition to allogeneic transplant in older patients
with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin
plus intensive chemotherapy.
Leuk Lymphoma. 2024 Apr 18:1-4. doi: 10.1080/10428194.2024.2332506. PubMed
STEIN EM, Fathi AT, Harb WA, Colak G, et al Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and
tolerability of pelabresib in patients with myeloid malignancies.
Leuk Lymphoma. 2024;65:503-510. PubMedAbstract available
PARVIZ M, Agius R, Rotbain EC, Vainer N, et al Identifying CLL patients at high risk of atrial fibrillation on treatment using
machine learning.
Leuk Lymphoma. 2024;65:449-459. PubMedAbstract available
ALDOSS I, Clark MC, Wang X, Forman SJ, et al Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL:
are we there yet?
Leuk Lymphoma. 2024;65:440-448. PubMedAbstract available
March 2024
CORTES J, Jonas BA, Schiller G, Mims A, et al Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1
(mIDH1) acute myeloid leukemia (AML).
Leuk Lymphoma. 2024 Mar 27:1-8. doi: 10.1080/10428194.2024.2333451. PubMedAbstract available
MATTHEWS A, Fenu E, Skuli SJ, Harris JC, et al Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia:
a promising high sensitivity diagnostic approach.
Leuk Lymphoma. 2024 Mar 27:1-4. doi: 10.1080/10428194.2024.2332505. PubMed
ABDALLAH AM, Hafez H, Madney Y, Ahmed S, et al Predictive value of early molecular response to tyrosine kinase inhibitors in
pediatric patients with chronic myeloid leukemia.
Leuk Lymphoma. 2024 Mar 21:1-4. doi: 10.1080/10428194.2024.2331625. PubMed
LACZKO D, Poveda-Rogers C, Matthews AH, Snaith O, et al RAD21 mutations in acute myeloid leukemia.
Leuk Lymphoma. 2024 Mar 20:1-7. doi: 10.1080/10428194.2024.2328233. PubMedAbstract available
ZHU J, Xu M, Ru Y, Gong H, et al Comparison of valganciclovir versus foscarnet for the treatment of
cytomegalovirus viremia in adult acute leukemia patients after allogeneic
hematopoietic cell transplantation.
Leuk Lymphoma. 2024 Mar 12:1-9. doi: 10.1080/10428194.2024.2321322. PubMedAbstract available
February 2024
NASKAR S, Paul T, Kulkarni JD, Anand KC, et al TCF3::PBX1 fusion pediatric B acute lymphoblastic leukemia in disguise behind the
eyes - an unusual clinicopathologic presentation with hyperdiploid clone.
Leuk Lymphoma. 2024 Feb 26:1-5. doi: 10.1080/10428194.2024.2320827. PubMed
HOFER KD, Buhler MM, Roncador M, Rechsteiner M, et al Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups:
one step closer to unveiling the genetic odyssey.
Leuk Lymphoma. 2024 Feb 22:1-8. doi: 10.1080/10428194.2024.2315171. PubMedAbstract available
MURPHY L, Siegele B, Carstens B, Hartman L, et al A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with
high-risk therapy.
Leuk Lymphoma. 2024 Feb 19:1-5. doi: 10.1080/10428194.2024.2315159. PubMed
TANG K, Lipton JH Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era -
forgotten but not gone.
Leuk Lymphoma. 2024 Feb 9:1-10. doi: 10.1080/10428194.2024.2313626. PubMedAbstract available
YARED JA, Lee TY, Cooke CE, Johnson A, et al Disparity in treatment patterns among Medicare beneficiaries diagnosed with
chronic lymphocytic leukemia: an analysis of patient and contextual factors.
Leuk Lymphoma. 2024 Feb 7:1-11. doi: 10.1080/10428194.2024.2310150. PubMedAbstract available
EL-ASHWAH S, Salmanton-Garcia J, Bilgin YM, Itri F, et al The mortality of COVID-19 in CML patients from 2020 until 2022: results from the
EPICOVIDEHA survey.
Leuk Lymphoma. 2024;65:199-208. PubMedAbstract available
JOHNSON SM, Haberberger J, Galeotti J, Ramkissoon L, et al Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated
myeloid neoplasms.
Leuk Lymphoma. 2024;65:209-218. PubMedAbstract available
January 2024
LEI MM, Sorial MN, Lou U, Yu M, et al Real-world evidence of obinutuzumab and venetoclax in previously treated patients
with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Leuk Lymphoma. 2024 Jan 31:1-7. doi: 10.1080/10428194.2024.2310144. PubMedAbstract available
NASR AA, Fund X, Barreau S, Desterke C, et al BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic
lymphocytic leukemia (CLL).
Leuk Lymphoma. 2024 Jan 31:1-4. doi: 10.1080/10428194.2024.2308665. PubMed
TADMOR T, Levy Yurkovski I Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy
cell leukemia.
Leuk Lymphoma. 2024 Jan 22:1-4. doi: 10.1080/10428194.2024.2304026. PubMed
FU S, Alhaj Z, Huynh D Prevalence of primary chronic lymphocytic leukemia in the United States: a
cross-sectional study using the SEER database.
Leuk Lymphoma. 2024 Jan 22:1-2. doi: 10.1080/10428194.2023.2300714. PubMed
BANERJI V, Aw A, Laferriere N, Abdel-Samad N, et al Management and use of healthcare resources in patients with chronic lymphocytic
leukemia initiating venetoclax in routine clinical practice.
Leuk Lymphoma. 2024 Jan 18:1-9. doi: 10.1080/10428194.2024.2301738. PubMedAbstract available
NGO D, Tinajero J, Li S, Palmer J, et al Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a
triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
Leuk Lymphoma. 2024 Jan 2:1-6. doi: 10.1080/10428194.2023.2292473. PubMedAbstract available
December 2023
SALTER B, Radford JM, Berg T, Leber B, et al The successful management of acute promyelocytic leukemia during pregnancy: a
case report.
Leuk Lymphoma. 2023 Dec 19:1-4. doi: 10.1080/10428194.2023.2295786. PubMed
MUTTI M, Cordella S, Parisotto A, Bettelli F, et al Characteristics and clinical behavior of acute myeloid leukemia harboring rare
non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience
and review of the literature.
Leuk Lymphoma. 2023 Dec 19:1-5. doi: 10.1080/10428194.2023.2294695. PubMed
WANG L, Gao L, Liang Z, Cen X, et al Efficacy and safety of coadministration of venetoclax and anti-fungal agents
under therapeutic drug monitor in unfit acute myeloid leukemia and high-risk
myelodysplastic syndrome with neutropenia: a single-center retrospective study.
Leuk Lymphoma. 2023 Dec 9:1-10. doi: 10.1080/10428194.2023.2290465. PubMedAbstract available
JEN WY, Sasaki K, Rausch CR, DiNardo CD, et al Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of
high dose arsenic trioxide in obese patients.
Leuk Lymphoma. 2023 Dec 6:1-5. doi: 10.1080/10428194.2023.2290467. PubMedAbstract available
ZHANG F, Hu GH, Zhang LP, Xu LP, et al Outcomes of haploidentical hematopoietic stem cell transplantation with 'Beijing
protocol' in pediatric myeloid neoplasms post cytotoxic therapy: a case series
study.
Leuk Lymphoma. 2023 Dec 3:1-6. doi: 10.1080/10428194.2023.2281276. PubMed
MURTON A, Forsyth C, Ross DM, Grigg A, et al Significant heterogeneity in management of calreticulin-mutated essential
thrombocythemia and its progression to myelofibrosis: results of a national
survey.
Leuk Lymphoma. 2023;64:2018-2025. PubMedAbstract available
STEIN EM, de Botton S, Cluzeau T, Pigneux A, et al Use of tamibarotene, a potent and selective RARalpha agonist, in combination with
azacitidine in patients with relapsed and refractory AML with RARA gene
overexpression.
Leuk Lymphoma. 2023;64:1992-2001. PubMedAbstract available
REDD RA, Ford J, Lei M, Abramson JS, et al Combined analysis of the impact of second-generation BTK inhibitors on patient
outcomes.
Leuk Lymphoma. 2023;64:2296-2305. PubMedAbstract available
YANG T, Mahmood N, Goldberg B, Cevallos J, et al Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement
presenting as de novo acute leukemias.
Leuk Lymphoma. 2023;64:2338-2342. PubMed
TOMASULO E, Paul S, Mu R, Tian X, et al Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination
in patients with CLL.
Leuk Lymphoma. 2023;64:2306-2315. PubMedAbstract available
SMITH AL, Pal D, Martinez-Rico R, Eiken AP, et al Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent
B-cell malignancies.
Leuk Lymphoma. 2023;64:2333-2337. PubMed
ZHANG X, Wang T, Zhang Y, Wang F, et al Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL
exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation.
Leuk Lymphoma. 2023;64:2133-2139. PubMedAbstract available
November 2023
LAI X, Xiao J, Wang T, Hou C, et al Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in
acute myeloid leukemia patients with allogeneic hematopoietic stem cell
transplantation during complete remission.
Leuk Lymphoma. 2023 Nov 22:1-9. doi: 10.1080/10428194.2023.2284089. PubMedAbstract available
OU J, Xu X, Deng S, Liang H, et al Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated
with a pediatric-type regimen.
Leuk Lymphoma. 2023 Nov 8:1-9. doi: 10.1080/10428194.2023.2278026. PubMedAbstract available
FATIMA N, Best OG, Belov L, Christopherson RI, et al The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells.
Leuk Lymphoma. 2023 Nov 7:1-8. doi: 10.1080/10428194.2023.2275530. PubMedAbstract available
KHOUDERCHAH CJ, Benitez LL, Marini BL, Fraga M, et al Tumor lysis syndrome in patients with acute myeloid leukemia treated with
venetoclax and hypomethylating agents with or without dose ramp-up.
Leuk Lymphoma. 2023 Nov 6:1-7. doi: 10.1080/10428194.2023.2276056. PubMedAbstract available
SASTOW D, Tatarian J, Salib C, Lin TL, et al Response to 'blast identification in cerebrospinal fluid specimens from patients
with acute myeloid leukemia: laboratory perspectives'.
Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2274658. PubMed
FRATER JL Blast identification in cerebrospinal fluid specimens from patients with acute
myeloid leukemia: laboratory perspectives.
Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2273749. PubMed
SOSNIA O, Pruszczyk K, Danecki M, Wasik-Szczepanek E, et al Richter transformation - retrospective treatment outcomes analysis in Polish
Adult Leukemia Study Group.
Leuk Lymphoma. 2023 Nov 3:1-12. doi: 10.1080/10428194.2023.2277140. PubMedAbstract available
TRINQUAND A, Betts DR, Harte S, Sills A, et al Adapted risk stratification and intensive chemotherapy abrogate the poor
prognosis of pediatric B acute lymphoblastic leukemia with intrachromosomal
amplification of chromosome 21 (iAMP21): a National cohort analysis.
Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276061. PubMed
RAMACHANDRA N, Gupta M, Schwartz L, Todorova T, et al Role of IL8 in myeloid malignancies.
Leuk Lymphoma. 2023;64:1742-1751. PubMedAbstract available
ITONAGA H, Kato T, Sawayama Y, Katsuoka S, et al RAISING revealed a heterogenous pattern of HTLV-1 clonality after
HLA-haploidentical peripheral blood stem cell transplantation for ATL.
Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276058. PubMed
October 2023
MERIC N, Albayrak E, Gulbas Z, Kocabas F, et al MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by
inducing apoptosis.
Leuk Lymphoma. 2023 Oct 30:1-12. doi: 10.1080/10428194.2023.2275532. PubMedAbstract available
CONTRERAS YAMETTI GP, Robbins G, Chowdhury A, Narang S, et al SETD2 mutations do not contribute to clonal fitness in response to chemotherapy
in childhood B cell acute lymphoblastic leukemia.
Leuk Lymphoma. 2023 Oct 24:1-13. doi: 10.1080/10428194.2023.2273752. PubMedAbstract available
HUNTINGTON SF, de Nigris E, Puckett J, Kamal-Bahl S, et al Ibrutinib discontinuation and associated factors in a real-world national sample
of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
Leuk Lymphoma. 2023 Oct 23:1-10. doi: 10.1080/10428194.2023.2256911. PubMedAbstract available
LIAO C, Nie J, Xu XJ, Zhang JY, et al The effect of the plasma methotrexate concentration during high-dose methotrexate
therapy in childhood acute lymphoblastic leukemia.
Leuk Lymphoma. 2023 Oct 11:1-9. doi: 10.1080/10428194.2023.2266075. PubMedAbstract available
ZAHID MF, Kainthla R Sustained long-term remission with tyrosine kinase inhibitor therapy in
treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2
fusion gene.
Leuk Lymphoma. 2023 Oct 9:1-5. doi: 10.1080/10428194.2023.2264428. PubMed
GAUT D, Oliai C, Boiarsky J, Zhang S, et al Measurable residual disease conversion rate with consolidation chemotherapy in
acute myeloid leukemia.
Leuk Lymphoma. 2023 Oct 6:1-9. doi: 10.1080/10428194.2023.2264426. PubMedAbstract available
YASU T, Gando Y, Shirota M, Kosugi N, et al Association between plasma venetoclax trough levels and serum C-reactive protein
levels in patients with acute myeloid leukemia treated with venetoclax plus
azacitidine.
Leuk Lymphoma. 2023 Oct 5:1-4. doi: 10.1080/10428194.2023.2264427. PubMed
SABILE JMG, Kaempf A, Tomic K, Manu GP, et al A retrospective validation of the IPSS-M molecular score in primary and
therapy-related myelodysplastic syndromes (MDS).
Leuk Lymphoma. 2023;64:1689-1694. PubMedAbstract available
CHAI J, Choudhuri J, Wang Q, Fang Y, et al Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1
upregulation.
Leuk Lymphoma. 2023;64:1662-1672. PubMedAbstract available
September 2023
LI L, Zhang R, Cao W, Bian Z, et al Comparative analysis of hypomethylating agents as maintenance therapy after
allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Leuk Lymphoma. 2023 Sep 21:1-10. doi: 10.1080/10428194.2023.2252948. PubMedAbstract available
HUNTINGTON SF, Manzoor BS, Puckett JT, Kamal-Bahl S, et al Real-world adherence and discontinuation among Medicare beneficiaries initiating
venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
Leuk Lymphoma. 2023 Sep 21:1-8. doi: 10.1080/10428194.2023.2255326. PubMedAbstract available
LESEGRETAIN A, Brunner A, Benzohra A, Fathi AT, et al Temporal trend in survival for chronic myelomonocytic leukemia in the US: a
population-based study.
Leuk Lymphoma. 2023 Sep 15:1-9. doi: 10.1080/10428194.2023.2252123. PubMedAbstract available
IELO C, Scalzulli E, Carmosino I, Pepe S, et al Validation of imatinib therapy failure score (IMTF) in chronic phase chronic
myeloid leukemia in real life practice.
Leuk Lymphoma. 2023 Sep 10:1-3. doi: 10.1080/10428194.2023.2255804. PubMedAbstract available
LA J, Lee MH, Brophy MT, Do NV, et al Baseline correlates of frailty and its association with survival in United States
veterans with acute myeloid leukemia.
Leuk Lymphoma. 2023 Sep 6:1-10. doi: 10.1080/10428194.2023.2254434. PubMedAbstract available
BHATNAGAR B, Zhao Q, Mims AS, Vasu S, et al Phase 1 study of selinexor in combination with salvage chemotherapy in Adults
with relapsed or refractory Acute myeloid leukemia.
Leuk Lymphoma. 2023 Sep 4:1-10. doi: 10.1080/10428194.2023.2253480. PubMedAbstract available